

non-small cell lung cancer: A british thoracic oncology group review. Annals of Oncology. 2022;33:S1061-S1062.

14. Novello S, Maimon N, Stevenson JP, et al. 7mo sotorasib in kras g12c-mutated advanced non-small cell lung cancer (anscl): Overall survival (os) data from the global expanded access program (eap study-436). Journal of Thoracic Oncology. 2023;18:S40-S41.

15. Passiglia F, Reale ML, Lo Russo G, et al. Sotorasib in krasp. G12c mutated advanced nscl: Real-world data from the italian expanded access program. Lung Cancer. 2024;187:107444.

16. Chen QA, Lin WH, Zhou XX, et al. Outcomes following kras(g12c) inhibitor treatment in patients with kras(g12c)-mutated solid tumors: A systematic review and meta-analysis. Pharmacol Res. 2024;200:107060.

17. Di Federico A, Riccotti I, Favorito V, et al. Resistance to kras g12c inhibition in non-small cell lung cancer. Curr Oncol Rep. 2023;25:1017-1029.

18. Batrash F, Kutmah M, Zhang J. The current landscape of using direct inhibitors to target kras(g12c)-mutated nscl. Exp Hematol Oncol. 2023;12:93.

19. Santarpia M, Ciappina G, Spagnolo CC, et al. Targeted therapies for kras-mutant non-small cell lung cancer: From preclinical studies to clinical development-a narrative review.

Transl Lung Cancer Res. 2023;12:346-368.

20. Zhang L, Chen W, Wei H, et al. Efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients with kras mutations: A network meta-analysis. Clin Respir J. 2024;18:e13745.

21. Chen W, Li L, Cheng S, et al. The efficacy of immune checkpoint inhibitors vs. Chemotherapy for kras-mutant or egfr-mutant non-small-cell lung cancers: A meta-analysis based on randomized controlled trials. Dis Markers. 2022;2022:2631852.

22. Landre T, Justeau G, Assié JB, et al. Anti-pd-(l)1 for kras-mutant advanced non-small-cell lung cancers: A meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022;71:719-726.

23. Mellema WW, Dingemans AM, Thunnissen E, et al. Kras mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. J Thorac Oncol. 2013;8:1190-1195.

24. Brady AK, McNeill JD, Judy B, et al. Survival outcome according to kras mutation status in newly diagnosed patients with stage iv non-small cell lung cancer treated with platinum doublet chemotherapy. Oncotarget. 2015;6:30287-30294.

25. Hames ML, Chen H, Iams W, et al. Correlation between kras mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer. Lung Cancer. 2016;92:29-34.

26. Levy B, Seetharamu N, Richardson S, et al. Kras mutations and outcomes for patients with stage iv nscl treated with frontline platinum/pemetrexed based chemotherapy. Journal of Clinical Oncology. 2012;30:e18139-e18139.

27. Wang MM, Zhang Y, Wu S, et al. Clinical outcomes of kras-mutant non-small cell lung cancer under untargeted therapeutic regimes in the real world: A retrospective observational study. Transl Lung Cancer Res. 2023;12:2030-2039.

28. Lewis J, Woodhouse L, Adderley H, et al. 78 – outcomes for platinum doublet chemotherapy before and after first-line immune checkpoint inhibition in advanced non-small cell lung cancer (nscl). Lung Cancer. 2023;178:S34.

29. Cortellini A, Cannita K, Tiseo M, et al. Post-progression outcomes of nscl patients with pd-l1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study. Eur J Cancer. 2021;148:24-35.

30. Torres-Jiménez J, Espinar JB, de Cabo HB, et al. Targeting kras(g12c) in non-small-cell lung cancer: Current standards and developments. Drugs. 2024;84:527-548.

33. MORAVSKÝ MEZIKRAJSKÝ SEMINÁŘ PRO PNEUMOLOGY

11. BESKYDSKÉ PNEUMONKOLOGICKÉ DNY



11.–12. 4. 2025
Hotel Soláň, Karolinka

ODBORNÍ GARANTI AKCE

- MUDr. Petr Jakubec, Ph.D.
- prim. MUDr. Gustáv Ondrejka, Ph.D.
- prim. MUDr. Jiří Pejchal
- prim. MUDr. Jaromír Roubec, Ph.D.
- prof. MUDr. Jana Skříčková, CSc.
- prof. MUDr. Milan Sova, Ph.D.

POŘADATEL

- SOLEN, s. r. o., ve spolupráci s Klinikou plicních nemocí a tuberkulózy FN Olomouc



Hlavní témata

PÁTEK 11. 4. 2025

- Obstrukce dýchacích cest
- Intersticiální plicní procesy
- Funkční vyšetření
- Bronchologie
- Zajímavé kazuistiky

■ ORGANIZAČNÍ ZAJIŠTĚNÍ A PŘIHLÁŠKY K AKTIVNÍ ÚČASTI

Mgr. Marta Boučková
tel. 770 194 701, bouckova@solen.cz

■ REGISTRACE K PASIVNÍ ÚČASTI A UBYTOVÁNÍ

Eliška Pančochová, DiS.
tel. 607 190 210, pancochova@solen.cz

SOBOTA 12. 4. 2025

- Diagnostické metody nitrohrudních nádorů
- Operační léčba karcinomu plic
- Novinky v biologické cílené léčbě karcinomu plic
- Kazuistiky v pneumoonkologii

PŘIHLÁŠKY K PASIVNÍ ÚČASTI

- do 6. 4. 2025, prostřednictvím registračního formuláře na www.kongrespneumologie.cz, nebo e-mailem na registrace@solen.cz

Účast bude v rámci celoživotního postgraduálního vzdělávání dle Stavovského předpisu č. 16 ČLK ohodnocena kredity pro lékaře.